ACE Inhibitors and ARBs in Chronic Kidney Disease

Primary Indications for ACEI/ARB Therapy

• The American College of Cardiology recommends that patients with diabetes, hypertension, and albuminuria should receive ACEI or ARB therapy regardless of CKD stage 1, 2
• Patients with CKD stages G1-G4 and moderately-to-severely increased albuminuria benefit from RAAS blockade independent of diabetes status 2
• Those with severe albuminuria or eGFR <60 mL/min/1.73 m² should receive these agents as first-line therapy even if normotensive 1, 3

Dosing Strategy

• The Kidney Disease: Improving Global Outcomes (KDIGO) guideline suggests titrating ACEI/ARB to maximum approved doses that are tolerated, as clinical trials demonstrating efficacy used these doses 1, 2

Monitoring Requirements

• The National Kidney Foundation recommends checking serum creatinine, eGFR, and potassium within 2-4 weeks of initiation or dose increase 1, 2
• Continue therapy if creatinine rises <30% within 4 weeks 1, 2
• Continue ACEI/ARB even when eGFR falls below 30 mL/min/1.73 m² 2

Managing Hyperkalemia

• The American Heart Association recommends managing hyperkalemia with potassium-lowering measures rather than immediately stopping ACEI/ARB 1, 2
• Moderate dietary potassium intake 1
• Correct volume depletion 1
• Only reduce dose or discontinue for uncontrolled hyperkalemia despite medical management 1, 2

Advanced CKD Considerations (Stages 4-5)

• The American Journal of Kidney Diseases suggests continuing ACEI/ARB in advanced CKD unless symptomatic hypotension, uncontrolled hyperkalemia, or uremic symptoms develop 2
• Consider dose reduction or discontinuation when eGFR <15 mL/min/1.73 m² to reduce uremic symptoms 1, 2

Critical Contraindications and Warnings

• The Kidney International journal recommends never combining ACEI with ARB or adding a direct renin inhibitor—this increases adverse events without additional cardiovascular or kidney benefits 1, 2
• Discontinue immediately if pregnancy is detected or planned 1

Common Pitfalls to Avoid

• Stopping therapy prematurely for modest creatinine increases (<30%) represents expected hemodynamic changes from reduced intraglomerular pressure, not kidney injury 1, 2
• Underdosing due to fear of adverse effects: maximum tolerated doses provide optimal renoprotection 1, 2

Integration with SGLT2 Inhibitors

• The American Journal of Kidney Diseases recommends adding SGLT2 inhibitors to ACEI/ARB therapy (not substituted) in patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 1, 2